# An Open Label Access Study For Subjects Who Completed A1481156

> **NCT01582438** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Access program - sildenafil citrate, Viagra, Revatio

## Key facts

- **NCT ID:** NCT01582438
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582438, "An Open Label Access Study For Subjects Who Completed A1481156". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01582438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*